Pooled analyses showed that the rate of pulmonary exacerbations was 30 to 39 % lower in the lumacaftor-ivacaftor groups than in the placebo group ; the rate of events leading to hospitalization or the use of intravenous antibiotics was lower in the lumacaftor-ivacaftor groups as well .